Franz Humer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(Bloomberg) -- Kallyope Inc., a US biotech that’s developing oral weight loss drugs, is exploring an initial public offering, according to people familiar with the matter, as the company seeks to capitalize on the investor frenzy around treatments for obesity. Most Read from BloombergChina Weighs Stock Market Rescue Package Backed by $278 BillionApple Dials Back Car’s Self-Driving Features and Delays Launch to 2028Netflix Pays $5 Billion for ‘Raw’ in Bet on Live EventsAn Isolated Israel Doubles

By Gisela Sommer,  Epoch Times | September 2, 2013 Last Updated: September 2, 2013 10:50 pm A screen shot from the mini documentary, "Killed for Organs: China's Secret State Transplant Business." The German newspaper Die Zeit points to Western complicity in the ongoing organ pillaging in China. (Courtesy of NTD Television) In China, one gets…

--Appointment strengthens Company's global management team, brings vast capital market expertise, unique network in the global financial community, and robust operational industry experience-- --Appointment

HMNC Brain Health Embarks on Next Phase of Growth with New Leadership Team Dr. Hans Eriksson appointed Chief Clinical Development Officer Dr. Franz Humer strengthens Board of Directors as Chairman Founder Prof. Dr. Dr. Dr. h.c. mult. Florian Holsboer to lead Scientific Advisory Board MUNICH, GERMANY / ACCESSWIRE / April 22, 2021 / HMNC Brain Health, a biotech company focused on the development of innovative and personalized treatments for depression and other neuropsychiatric disorders, enters a new phase of growth with a new leadership team. Benedikt von Braunmühl, formerly COO, Diagnostic ...